PróGenéricos

What PróGenéricos does

Pr\u00f3Gen\u00e9ricos (legal name: Pr\u00f3Gen\u00e9ricos \u2013 Associa\u00e7\u00e3o Brasileira das Ind\u00fastrias de Medicamentos Gen\u00e9ricos e Biossimilares) is a Brazilian non-profit industry association founded in 2001 that represents pharmaceutical manufacturers dedicated to the research, production, and commercialization of generic and biosimilar medicines in Brazil. Originally focused exclusively on generics, the association expanded its scope in 2021 to include biosimilars. It is the sole national trade body dedicated to these categories and represents 13 member companies \u2014 a mix of large Brazilian pharmaceutical firms (EMS, Eurofarma, Hypera, Prati-Donaduzzi, Cimed, Geolab, Brainfarma, Biossint\u00e9tica, Neo Qu\u00edmica, Nova Qu\u00edmica) and international manufacturers operating locally (Dr. Reddy's, Sandoz Brazil, Fresenius Kabi Brazil) \u2014 whose combined market share is 20% of the Brazilian pharmaceutical market.

The association's core activities span four functional pillars: regulatory affairs (active participation in ANVISA public consultations and the development of Technical Note 60/2026 on biosimilar interchangeability), government articulation (lobbying ministries, parliamentarians, and regulatory agencies), institutional dialogue (engagement with class entities, health organizations, and PAHO), and intellectual property monitoring (combating improper patent term extensions, including via judicial action that contributed to the December 2025 STJ ruling validating INPI's patent-term position). It sponsors the LogMed reverse-logistics system for discarded medicines and organizes industry events such as Conex\u00e3o Biossimilares and serves as Strategic Partner of Biosimilars LatAm \u2013 Brazil 2026.

Pr\u00f3Gen\u00e9ricos operates on a non-profit membership model funded by monthly fees calculated as a percentage of each member company's market share. It is governed by an Administrative Council elected from among its members, currently chaired by Eder Fernando Maffissoni (CEO of Prati-Donaduzzi) for the 2026-2028 term, with executive leadership provided by Executive President Tiago de Moraes Vicente (appointed 2023 alongside the headquarters relocation from S\u00e3o Paulo to Bras\u00edlia). The association is a member of the International Generic and Biosimilar Medicines Association (IGBA), providing members with global regulatory intelligence and best practices. The association operates in a Brazilian pharmaceutical market valued at approximately R$ 178 billion (2023), the 7th largest globally and largest in Latin America, where generic medicines represent roughly 40% of total sales.

Name

PróGenéricos

Legal name

PRÓGENÉRICOS – ASSOCIAÇÃO BRASILEIRA DAS INDÚSTRIAS DE MEDICAMENTOS GENÉRICOS E BIOSSIMILARES

Website

https://progenericos.org.br

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Pr\u00f3Gen\u00e9ricos is a Brazilian non-profit industry association founded in 2001 representing pharmaceutical manufacturers of generic and biosimilar medicines. It advocates on regulatory, governmental, and intellectual property matters before ANVISA, funded by market-share-based membership fees from 13 member companies.

Ownership category

akta.pro rank

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Membership Fees: PróGenéricos operates as an industry association funded through monthly membership fees calculated based on each member company's market share. This ensures contributions proportional to company size and market position.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

PróGenéricos is the Brazilian Association of Generic and Biosimilar Drug Manufacturers (Associação Brasileira das Indústrias de Medicamentos Genéricos e Biossimilares), a non-profit trade association that represents Brazilian pharmaceutical companies dedicated to the research, production, and commercialization of generic and biosimilar medicines. It provides policy advocacy, regulatory affairs support, government liaison, market intelligence, and sector coordination to its member companies, serving as the unified voice of the generics and biosimilars industry before ANVISA and other stakeholders.

Product overview

PróGenéricos is an industry association (Associação Brasileira das Indústrias de Medicamentos Genéricos e Biossimilares) that represents Brazilian pharmaceutical companies dedicated to the research, production, and commercialization of generic and biosimilar medicines. The organization does not offer traditional software products or services; instead, it provides industry representation, regulatory affairs support, advocacy, market intelligence, and networking services to its member companies. The association's activities include participating in public consultations with ANVISA, monitoring intellectual property matters, facilitating logistics reverse systems, and organizing industry events such as Conexão Biossimilares and the Biosimilars LatAm forums.

Differentiator

Problem solved

Functional benefit

Products and services

• Regulatory Affairs Advocacy

Quantifiable outcome

• Over 2 billion units of generics commercialized and more than R$ 300 billion in savings for the population since 1999
• +5 more outcomes

Named customers13 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Twelve partnerships are on record, tiered core and minor.

• JackLeckerman (Biosimilars LatAm - Brazil 2026)coreGTM or Marketing Partner · 29 June 2026PróGenéricos is a Strategic Partner of the Biosimilars LatAm – Brazil 2026 event. The association offers members a 10% discount on registration fees using code LAPH139PROGENERICOSASSO322. The event brings together regulators, manufacturers, and specialists shaping the future of biosimilars, with confirmed participation from ANVISA, INVIMA (Colombia), COFEPRIS (Mexico), and PAHO.
• ANVISA (Agência Nacional de Vigilância Sanitária)coreStrategic or Co-development Partner · 11 June 2026PróGenéricos collaborates actively with ANVISA on public consultations and regulatory policy development for generic and biosimilar medicines. The association participated in the Conexão Biossimilares event alongside ANVISA's full board of directors, marking the presentation of ANVISA's Technical Note No. 60/2026 on interchangeability of biosimilars and biological medicines.
• Abifina (Associação Brasileira das Indústrias de Química Fina)minorStrategic or Co-development Partner · 11 June 2026Supporting partner of the Conexão Biossimilares event organized by PróGenéricos and sector entities.
• Acessa (Associação Brasileira da Indústria de Produtos para o Autocuidado em Saúde)minorStrategic or Co-development Partner · 11 June 2026Supporting partner of the Conexão Biossimilares event organized by PróGenéricos and sector entities.
• Alanac (Associação dos Laboratórios Farmacêuticos Nacionais)minorStrategic or Co-development Partner · 11 June 2026Supporting partner of the Conexão Biossimilares event organized by PróGenéricos and sector entities.
• Grupo FarmaBrasilminorStrategic or Co-development Partner · 11 June 2026Supporting partner of the Conexão Biossimilares event organized by PróGenéricos and sector entities.
• Sindusfarma (Sindicato da Indústria de Produtos Farmacêuticos)minorStrategic or Co-development Partner · 11 June 2026Supporting partner of the Conexão Biossimilares event organized by PróGenéricos and sector entities. Also a partner in joint industry advocacy.
• Sindifargo (Sindicato das Indústrias Farmacêuticas no Estado de Goiás)minorStrategic or Co-development Partner · 11 June 2026Supporting partner of the Conexão Biossimilares event organized by PróGenéricos and sector entities.
• Complexo Industrial e Portuário de SuapeminorStrategic or Co-development Partner · 27 May 2025PróGenéricos received representatives of the Suape Industrial and Port Complex for an Extraordinary General Assembly and Administrative Council meeting, exploring potential industrial and port integration for the pharmaceutical sector.
• Sinovac BiotechminorStrategic or Co-development Partner · 13 May 2025Eurofarma (PróGenéricos member) announced a partnership with Sinovac Biotech to propose the creation of an institute, demonstrating member-level international collaboration facilitated by PróGenéricos membership network.
• LogMed (Sistema de Logística Reversa de Medicamentos)coreStrategic or Co-development PartnerPróGenéricos is a sponsoring organization of the reverse logistics system operated by LogMed, a management entity integral to Brazil's National Solid Waste Policy. LogMed handles complete reverse logistics execution including collection of discarded medicines, transportation, environmentally appropriate disposal, and documentation for authorities. Members receive facilitated access to the reverse logistics system with all legal requirements already met, ensuring compliance with Decree No. 10.388/2020.
• IGBA (International Generic and Biosimilar Medicines Association)coreStrategic or Co-development PartnerIGBA represents the global generic and biosimilar medicines industry, promoting access to quality, safe, effective, and cost-effective treatments worldwide. PróGenéricos is Brazil's representative in this international network, providing members with direct access to global regulatory and market trends, legislative changes in other countries, and technical discussions adopted by other regulatory agencies. This partnership offers strategic vision on sector direction and strengthens members' competitiveness.

Scale indicators20 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• IGBA (International Generic and Biosimilar Medicines Association): The global umbrella association for generic and biosimilar medicine manufacturers, of which PróGenéricos is Brazil's national member. IGBA operates with an almost identical mandate — policy advocacy, regulatory intelligence, and international representation for the generic and biosimilar industry.
• AAM (Association for Accessible Medicines): U.S. trade association representing generic and biosimilar manufacturers, with parallel policy advocacy, regulatory engagement, and market-access mandate to PróGenéricos in the U.S. context.
• Alanac (Associação dos Laboratórios Farmacêuticos Nacionais): Brazilian association of national pharmaceutical laboratories operating in the same domestic market as PróGenéricos, with overlapping membership and complementary — but competing — policy advocacy mandate.
• Medicines for Europe: The European trade association representing generic and biosimilar manufacturers. It is functionally the closest international analogue to PróGenéricos, pursuing the same regulatory advocacy and market-access mission across a different geography.
• Canadian Generic Pharmaceutical Association (CGPA): Canada's national association for generic pharmaceutical manufacturers, also a member of IGBA alongside PróGenéricos. Pursues parallel policy, pricing, and regulatory advocacy goals in a different national jurisdiction.

Emerging players

• Indian Pharmaceutical Alliance (IPA): Indian pharma industry body focused on generic manufacturers operating internationally. Comparable as an emerging-market generic advocacy organization, though larger and more focused on export competitiveness than domestic policy.

Regional players

• Grupo FarmaBrasil: Brazilian pharma industry group representing major national manufacturers, with overlapping advocacy goals on pharmaceutical regulation and industrial policy in Brazil.
• Sindusfarma (Sindicato da Indústria de Produtos Farmacêuticos): São Paulo-based pharmaceutical industry union representing manufacturers in Brazil. Competes with PróGenéricos for industry representation and was a supporting partner at the Conexão Biossimilares event.
• FIFARMA (Federación Latinoamericana de la Industria Farmacéutica): Latin American pharmaceutical industry federation serving as a regional umbrella for national pharma associations, comparable to PróGenéricos's IGBA relationship but for Latin America rather than the global generics/biosimilars space.

Broad incumbents

• Interfarma (Associação da Indústria Farmacêutica de Pesquisa): Brazil's main association for research-based (innovative) pharmaceutical companies. Operates in the same geography with broader scope and represents a broader industry perspective, sometimes diverging from PróGenéricos on IP and pricing policy.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Progenericos_
• Facebookfacebook.com/associacaoprogenericos

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PróGenéricos